Additions and Corrections

2003, Volume 46

Asim Kumar Debnath*: Generation of Predictive Pharmacophore Models for CCR5 Antagonists: Study with Piperidine- and Piperazine-Based Compounds as a New Class of HIV-1 Entry Inhibitors.

Page 4512. The double-plus signs in the last column of Table 6 should be single plus signs. The corrected Table 6 is shown below.

Table 6. Results of Validation with Five Marketed CNS Drugs (Negative Control) Known To Target GPCR Receptors Other than CCR5

Name of the Marketed Drug **(Company)**[a]	Target GPCR of the Drug	Structure of the Drug[b]	K_i (nM) Estimated[c]	Activity Scale
Ropinirole **(GlaxoSmithKline)**	Dopamine (D2/D3)		310	+
Sumatriptan **(GlaxoSmithKline)**	Serotonin (5-HT1D)		320	+
Clozapine **(Novartis)**	Serotonin (5-HT2A/2C)		7128	-
Buprenorphine **(Reckitt Benckiser)**	Opioid (K)		410	+
Morphine **(AstraZeneca, Purdue Frederick, Roxane, Elkins-Sinn, Faulding)**	Opioid (μ)		5700	-

[a] Obtained from Physician's Desk Reference (PDR), 2002. [b] Sturcutres obtained from http://chembank.med.harvard.edu/bioactives/. [c] Estimated based on Hypothesis-1.

JM0306071

10.1021/jm0306071
Published on Web 01/06/2004